Neuronetics Stock
Neuronetics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Daniel L. Reuvers
- Employees
- 658
- Market cap
- $144 M
- IPO
- 28/06/2018
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced…
Neuronetics stock: price history
1D
-3.3%
1W
-11.5%
1M
-31.7%
6M
+32.7%
YTD
+36.6%
1Y
-34.5%
2Y
+105.8%
5Y
-61.2%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~130% stronger price swings than usual
Ask the agents about Neuronetics
Analyst assessment of Neuronetics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 17/09/2026
Neuronetics stock metrics
P/E
-4.38
P/B
7.54
EV/EBITDA
-10.67
RETURN ON EQUITY
-19.3%
NET MARGIN
-8.3%
DEBT/EQUITY
4.85
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
37.9%
FLOAT SHARES
28,881,253
AVG. DAILY VOLUME (30D)
1,113,375
Insider transactions (SEC)
Chernett Jorey
Naor Nir
Chernett Jorey
Madryn Asset Management, LP
Madryn Asset Management, LP
Institutional holders
Comparable stocks
Frequently asked questions about Neuronetics stock
What does Neuronetics do?
Neuronetics, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Daniel L. Reuvers, the company employs around 658 people.
The IPO was on 28/06/2018; the stock trades on NASDAQ under the ticker STIM.
What do analysts say about Neuronetics stock?
7 analysts rate the stock, the consensus is Buy (as of 17/09/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Neuronetics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 130% stronger than usual.
Does Neuronetics pay a dividend?
No, Neuronetics currently does not pay a dividend.
Which stocks are comparable to Neuronetics?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Neuronetics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Neuronetics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.